Circulating fibrosis biomarkers and risk of atrial fibrillation: The Cardiovascular Health Study (CHS)

Michael A. Rosenberg, Marlena Maziarz, Alex Y. Tan, Nicole L. Glazer, Susan J. Zieman, Jorge Kizer, Joachim H. Ix, Luc Djousse, David S. Siscovick, Susan R. Heckbert, Kenneth J. Mukamal

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background Cardiac fibrosis is thought to play a central role in the pathogenesis of atrial fibrillation (AF). Retrospective studies have suggested that circulating fibrosis biomarkers are associated with AF, but prospective studies are limited. Methods We measured circulating levels of 2 fibrosis biomarkers, procollagen type III, N-terminal propeptide (PIIINP) and transforming growth factor β1 among participants of the CHS, a population-based study of older Americans. We used Cox proportional hazards and competing risks models to examine adjusted risk of incident AF over a median follow-up of 8.8 years. Results Levels of PIIINP were assessed in 2,935 participants, of whom 767 developed AF. Compared with the median PIIINP level (4.45 μg/L), adjusted hazard ratios (95% CIs) were 0.85 (0.72-1.00) at the 10th percentile, 0.93 (0.88-0.99) at the 25th percentile, 1.04 (0.95-1.04) at the 75th percentile, and 1.07 (0.90-1.26) at the 90th. Transforming growth factor β1 levels, assessed in 1,538 participants with 408 cases of incident AF, were not associated with AF risk. Conclusion In older adults, PIIINP levels were associated with risk of incident AF in a complex manner, with an association that appeared to be positive up to median levels but with little relationship beyond that. Further studies are required to confirm and possibly delineate the mechanism for this relationship.

Original languageEnglish (US)
JournalAmerican Heart Journal
Volume167
Issue number5
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Atrial Fibrillation
Fibrosis
Biomarkers
Collagen Type III
Health
Transforming Growth Factors
Retrospective Studies
Prospective Studies
Population

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Rosenberg, M. A., Maziarz, M., Tan, A. Y., Glazer, N. L., Zieman, S. J., Kizer, J., ... Mukamal, K. J. (2014). Circulating fibrosis biomarkers and risk of atrial fibrillation: The Cardiovascular Health Study (CHS). American Heart Journal, 167(5). https://doi.org/10.1016/j.ahj.2014.01.010

Circulating fibrosis biomarkers and risk of atrial fibrillation : The Cardiovascular Health Study (CHS). / Rosenberg, Michael A.; Maziarz, Marlena; Tan, Alex Y.; Glazer, Nicole L.; Zieman, Susan J.; Kizer, Jorge; Ix, Joachim H.; Djousse, Luc; Siscovick, David S.; Heckbert, Susan R.; Mukamal, Kenneth J.

In: American Heart Journal, Vol. 167, No. 5, 2014.

Research output: Contribution to journalArticle

Rosenberg, MA, Maziarz, M, Tan, AY, Glazer, NL, Zieman, SJ, Kizer, J, Ix, JH, Djousse, L, Siscovick, DS, Heckbert, SR & Mukamal, KJ 2014, 'Circulating fibrosis biomarkers and risk of atrial fibrillation: The Cardiovascular Health Study (CHS)', American Heart Journal, vol. 167, no. 5. https://doi.org/10.1016/j.ahj.2014.01.010
Rosenberg, Michael A. ; Maziarz, Marlena ; Tan, Alex Y. ; Glazer, Nicole L. ; Zieman, Susan J. ; Kizer, Jorge ; Ix, Joachim H. ; Djousse, Luc ; Siscovick, David S. ; Heckbert, Susan R. ; Mukamal, Kenneth J. / Circulating fibrosis biomarkers and risk of atrial fibrillation : The Cardiovascular Health Study (CHS). In: American Heart Journal. 2014 ; Vol. 167, No. 5.
@article{d4f1d3770c4241858eabb842a86aade6,
title = "Circulating fibrosis biomarkers and risk of atrial fibrillation: The Cardiovascular Health Study (CHS)",
abstract = "Background Cardiac fibrosis is thought to play a central role in the pathogenesis of atrial fibrillation (AF). Retrospective studies have suggested that circulating fibrosis biomarkers are associated with AF, but prospective studies are limited. Methods We measured circulating levels of 2 fibrosis biomarkers, procollagen type III, N-terminal propeptide (PIIINP) and transforming growth factor β1 among participants of the CHS, a population-based study of older Americans. We used Cox proportional hazards and competing risks models to examine adjusted risk of incident AF over a median follow-up of 8.8 years. Results Levels of PIIINP were assessed in 2,935 participants, of whom 767 developed AF. Compared with the median PIIINP level (4.45 μg/L), adjusted hazard ratios (95{\%} CIs) were 0.85 (0.72-1.00) at the 10th percentile, 0.93 (0.88-0.99) at the 25th percentile, 1.04 (0.95-1.04) at the 75th percentile, and 1.07 (0.90-1.26) at the 90th. Transforming growth factor β1 levels, assessed in 1,538 participants with 408 cases of incident AF, were not associated with AF risk. Conclusion In older adults, PIIINP levels were associated with risk of incident AF in a complex manner, with an association that appeared to be positive up to median levels but with little relationship beyond that. Further studies are required to confirm and possibly delineate the mechanism for this relationship.",
author = "Rosenberg, {Michael A.} and Marlena Maziarz and Tan, {Alex Y.} and Glazer, {Nicole L.} and Zieman, {Susan J.} and Jorge Kizer and Ix, {Joachim H.} and Luc Djousse and Siscovick, {David S.} and Heckbert, {Susan R.} and Mukamal, {Kenneth J.}",
year = "2014",
doi = "10.1016/j.ahj.2014.01.010",
language = "English (US)",
volume = "167",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Circulating fibrosis biomarkers and risk of atrial fibrillation

T2 - The Cardiovascular Health Study (CHS)

AU - Rosenberg, Michael A.

AU - Maziarz, Marlena

AU - Tan, Alex Y.

AU - Glazer, Nicole L.

AU - Zieman, Susan J.

AU - Kizer, Jorge

AU - Ix, Joachim H.

AU - Djousse, Luc

AU - Siscovick, David S.

AU - Heckbert, Susan R.

AU - Mukamal, Kenneth J.

PY - 2014

Y1 - 2014

N2 - Background Cardiac fibrosis is thought to play a central role in the pathogenesis of atrial fibrillation (AF). Retrospective studies have suggested that circulating fibrosis biomarkers are associated with AF, but prospective studies are limited. Methods We measured circulating levels of 2 fibrosis biomarkers, procollagen type III, N-terminal propeptide (PIIINP) and transforming growth factor β1 among participants of the CHS, a population-based study of older Americans. We used Cox proportional hazards and competing risks models to examine adjusted risk of incident AF over a median follow-up of 8.8 years. Results Levels of PIIINP were assessed in 2,935 participants, of whom 767 developed AF. Compared with the median PIIINP level (4.45 μg/L), adjusted hazard ratios (95% CIs) were 0.85 (0.72-1.00) at the 10th percentile, 0.93 (0.88-0.99) at the 25th percentile, 1.04 (0.95-1.04) at the 75th percentile, and 1.07 (0.90-1.26) at the 90th. Transforming growth factor β1 levels, assessed in 1,538 participants with 408 cases of incident AF, were not associated with AF risk. Conclusion In older adults, PIIINP levels were associated with risk of incident AF in a complex manner, with an association that appeared to be positive up to median levels but with little relationship beyond that. Further studies are required to confirm and possibly delineate the mechanism for this relationship.

AB - Background Cardiac fibrosis is thought to play a central role in the pathogenesis of atrial fibrillation (AF). Retrospective studies have suggested that circulating fibrosis biomarkers are associated with AF, but prospective studies are limited. Methods We measured circulating levels of 2 fibrosis biomarkers, procollagen type III, N-terminal propeptide (PIIINP) and transforming growth factor β1 among participants of the CHS, a population-based study of older Americans. We used Cox proportional hazards and competing risks models to examine adjusted risk of incident AF over a median follow-up of 8.8 years. Results Levels of PIIINP were assessed in 2,935 participants, of whom 767 developed AF. Compared with the median PIIINP level (4.45 μg/L), adjusted hazard ratios (95% CIs) were 0.85 (0.72-1.00) at the 10th percentile, 0.93 (0.88-0.99) at the 25th percentile, 1.04 (0.95-1.04) at the 75th percentile, and 1.07 (0.90-1.26) at the 90th. Transforming growth factor β1 levels, assessed in 1,538 participants with 408 cases of incident AF, were not associated with AF risk. Conclusion In older adults, PIIINP levels were associated with risk of incident AF in a complex manner, with an association that appeared to be positive up to median levels but with little relationship beyond that. Further studies are required to confirm and possibly delineate the mechanism for this relationship.

UR - http://www.scopus.com/inward/record.url?scp=84899525953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899525953&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2014.01.010

DO - 10.1016/j.ahj.2014.01.010

M3 - Article

C2 - 24766983

AN - SCOPUS:84899525953

VL - 167

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 5

ER -